PR Newswire
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20 locations worldwide over the next 12 months.
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20 locations worldwide over the next 12 months.
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20 locations worldwide over the next 12 months.
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20 locations worldwide over the next 12 months.
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved hemoglobin levels and reduced anemia and fatigue
MISSISSAUGA, ON, July 23, 2024 /CNW/ - Voydeya (danicopan tablets) has been approved in Canada as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor.2,3
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4
ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation shared data indicating a manageable safety profile and encouraging anti-tumor activity of C-CAR031 in patients with heavily pretreated advanced hepatocellular carcinoma (HCC) (1-6 lines of prior therapy). C-CAR031 is based on a novel GPC3-targeting CAR-T designed by AstraZeneca (LSE/STO/Nasdaq: AZN) and is manufactured by AbelZeta. C-CAR031 is being co-developed in China by AbelZeta and AstraZeneca.
Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.
RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt.
Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.
Wir bedanken uns im Namen der Trading-Community bei den Betreibern der Handelsplätze für die Bereitstellung von Informationsdiensten.